Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer

NCT06284070 · tracked via the Priya Life Science China tracker

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase

Observational

Started

2024-01-01

Last updated

2024-02-28

Condition(s) studied

Cancer

Study summary

Cancer associated fibroblasts (CAFs) can promote tumor cell proliferation, migration, invasion, and angiogenesis through immunosuppressive effects and the production of mediators, thereby promoting tumor growth and progression. The characteristic of CAFs is high expression of fibroblast activation protein (FAP). In approximately 90% of epithelial derived tumors, FAP is highly overexpressed on the membrane of CAFs. Contrary to CAFs, FAP expression is lower or absent in normal tissues. Therefore, FAP inhibitors (FAPI) targeting FAP can overcome the limitations of 18F-2-fluoro.2-deoxy-D-glucose fluorodeoxyglucose(18F-FDG) PET imaging. But like 18F-FDG, wound healing, fibrosis, and inflammation can also uptake FAPI.. Therefore, a comparison of the performance of 18F-FDG and 18F-FAPI PET imaging in diagnosing primary and metastatic lesions of various types of cancer is conducted to evaluate the potential value of these new radiopharmaceuticals as effective alternatives to 18F-FDG, highlighting their advantages and limitations.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Adult patients (≥ 18 years old); 2. Suspected or newly diagnosed malignant tumor patients; 3. Patients who underwent 18F-FDG and 18F-FAPI PET scans within one week; 4. Patients who are able to provide informed consent forms (signed by participants, parents, or legal representatives) and consent forms in accordance with the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: 1. Pregnant women; 2. Scanned images with poor image quality due to factors such as body movement; 3. Patients with mental illness or other unsuitable conditions for examination, poor compliance, etc.

Primary outcome measure(s)

Diagnostic efficacy — Completed within half year after end of the study
The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 18F-FAPI PET were calculated and compared to evaluate the diagnostic efficacy.

Trial sites (1)

Facility	City	Region	Status
Department of Nuclear Medicine, Daping Hospital of Army Medical University	Chongqing	Chongqing Municipality	Recruiting

More Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials in China

CT and Endoscopic Biopsy Image-Based Deep Learning for Predicting Left Recurrent Laryngeal Nerve Lymph Node Metastasis in Esophageal Cancer Active, not recruiting

Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery Starting soon

Single-port Versus Multi-port Robotic Surgery for Rectal Cancer Recruiting

Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma Recruiting

Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis Recruiting

Other trials for the same condition

Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors Active, not recruiting

Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe Recruiting

Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT) Recruiting

Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer Recruiting

68Ga-NYM096 PET/CT in Various Kinds of Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06284070 on ClinicalTrials.gov ↗ ← All trials in China